Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 5, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2016-01-11
DOI
10.3389/fonc.2015.00304
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
- (2016) Marcello Tucci et al. EUROPEAN UROLOGY
- Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra
- (2015) K. Fizazi et al. ANNALS OF ONCOLOGY
- Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices
- (2015) Guru Sonpavde et al. Clinical Genitourinary Cancer
- Achievements and Perspectives in Prostate Cancer Phase 3 Trials from Genitourinary Research Groups in Europe: Introducing the Prostate Cancer Consortium in Europe
- (2015) Karim Fizazi et al. EUROPEAN UROLOGY
- A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).
- (2015) Howard M. Sandler et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial
- (2015) Karim Fizazi et al. LANCET ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer
- (2015) Eugene K. Cha et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
- (2014) M. Marin-Aguilera et al. MOLECULAR CANCER THERAPEUTICS
- Castration-resistant Prostate Cancer: Novel Therapeutics Pre- or Post- Taxane Administration
- (2013) Masaki Shiota et al. CURRENT CANCER DRUG TARGETS
- Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
- (2013) Gwenaelle Gravis et al. LANCET ONCOLOGY
- Interaction between docetaxel resistance and castration resistance in prostate cancer: Implications of twist1, YB-1, and androgen receptor
- (2013) Masaki Shiota et al. PROSTATE
- Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205
- (2012) Martin Puhr et al. AMERICAN JOURNAL OF PATHOLOGY
- Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial
- (2012) P-L Kellokumpu-Lehtinen et al. PROSTATE CANCER AND PROSTATIC DISEASES
- A phase III trial of docetaxel–estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial
- (2011) Karim Fizazi et al. EUROPEAN JOURNAL OF CANCER
- Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study
- (2011) Tanya B. Dorff et al. JOURNAL OF CLINICAL ONCOLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started